SUNSHINE BIOPHARMA INC (SBFM) Fundamental Analysis & Valuation

NASDAQ:SBFM • US8677817004

Current stock price

0.9715 USD
-0.07 (-6.59%)
Last:

This SBFM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. SBFM Profitability Analysis

1.1 Basic Checks

  • In the past year SBFM has reported negative net income.
  • SBFM had a negative operating cash flow in the past year.
  • In the past 5 years SBFM always reported negative net income.
  • In the past 5 years SBFM always reported negative operating cash flow.
SBFM Yearly Net Income VS EBIT VS OCF VS FCFSBFM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • The Return On Assets of SBFM (-19.87%) is better than 76.02% of its industry peers.
  • The Return On Equity of SBFM (-25.94%) is better than 78.14% of its industry peers.
Industry RankSector Rank
ROA -19.87%
ROE -25.94%
ROIC N/A
ROA(3y)-17.71%
ROA(5y)-141.82%
ROE(3y)-23.01%
ROE(5y)-1211.74%
ROIC(3y)N/A
ROIC(5y)N/A
SBFM Yearly ROA, ROE, ROICSBFM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2K -2K 4K -4K 6K

1.3 Margins

  • SBFM has a Gross Margin of 33.76%. This is in the better half of the industry: SBFM outperforms 72.92% of its industry peers.
  • In the last couple of years the Gross Margin of SBFM has declined.
  • The Profit Margin and Operating Margin are not available for SBFM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.74%
GM growth 5Y-12.22%
SBFM Yearly Profit, Operating, Gross MarginsSBFM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SBFM Health Analysis

2.1 Basic Checks

  • SBFM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SBFM has been increased compared to 1 year ago.
  • Compared to 5 years ago, SBFM has more shares outstanding
  • There is no outstanding debt for SBFM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SBFM Yearly Shares OutstandingSBFM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
SBFM Yearly Total Debt VS Total AssetsSBFM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • SBFM has an Altman-Z score of -1.53. This is a bad value and indicates that SBFM is not financially healthy and even has some risk of bankruptcy.
  • SBFM has a Altman-Z score (-1.53) which is in line with its industry peers.
  • SBFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.53
ROIC/WACCN/A
WACC9.17%
SBFM Yearly LT Debt VS Equity VS FCFSBFM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 4.17 indicates that SBFM has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.17, SBFM is in line with its industry, outperforming 49.71% of the companies in the same industry.
  • SBFM has a Quick Ratio of 2.08. This indicates that SBFM is financially healthy and has no problem in meeting its short term obligations.
  • SBFM has a worse Quick ratio (2.08) than 73.89% of its industry peers.
Industry RankSector Rank
Current Ratio 4.17
Quick Ratio 2.08
SBFM Yearly Current Assets VS Current LiabilitesSBFM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SBFM Growth Analysis

3.1 Past

  • SBFM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.45%, which is quite impressive.
  • Looking at the last year, SBFM shows a small growth in Revenue. The Revenue has grown by 4.10% in the last year.
  • The Revenue has been growing by 340.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)89.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%-10.61%

3.2 Future

  • Based on estimates for the next years, SBFM will show a very strong growth in Earnings Per Share. The EPS will grow by 41.20% on average per year.
  • SBFM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.04% yearly.
EPS Next Y98.01%
EPS Next 2Y41.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.21%
Revenue Next 2Y15.04%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SBFM Yearly Revenue VS EstimatesSBFM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
SBFM Yearly EPS VS EstimatesSBFM Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

1

4. SBFM Valuation Analysis

4.1 Price/Earnings Ratio

  • SBFM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SBFM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SBFM Price Earnings VS Forward Price EarningsSBFM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SBFM Per share dataSBFM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40 -50

4.3 Compensation for Growth

  • SBFM's earnings are expected to grow with 41.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.2%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SBFM Dividend Analysis

5.1 Amount

  • SBFM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SBFM Fundamentals: All Metrics, Ratios and Statistics

SUNSHINE BIOPHARMA INC

NASDAQ:SBFM (4/10/2026, 10:55:42 AM)

0.9715

-0.07 (-6.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-03
Earnings (Next)05-13
Inst Owners5.24%
Inst Owner Change0%
Ins Owners0%
Ins Owner Change0%
Market Cap4.77M
Revenue(TTM)36.31M
Net Income(TTM)-5.98M
Analysts82.86
Price Target6.12 (529.95%)
Short Float %3.4%
Short Ratio4.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-69.68%
Min EPS beat(2)-96.08%
Max EPS beat(2)-43.29%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.37%
Min Revenue beat(2)-16.82%
Max Revenue beat(2)-15.91%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.13
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.23
EV/EBITDA N/A
EPS(TTM)-51.88
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS7.39
BVpS4.69
TBVpS4.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.87%
ROE -25.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.76%
FCFM N/A
ROA(3y)-17.71%
ROA(5y)-141.82%
ROE(3y)-23.01%
ROE(5y)-1211.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.74%
GM growth 5Y-12.22%
F-Score5
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 251.82%
Cap/Sales 2.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.17
Quick Ratio 2.08
Altman-Z -1.53
F-Score5
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)555.21%
Cap/Depr(5y)575.19%
Cap/Sales(3y)3.75%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46%
EPS Next Y98.01%
EPS Next 2Y41.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.1%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%-10.61%
Revenue Next Year-0.21%
Revenue Next 2Y15.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.46%
OCF growth 3YN/A
OCF growth 5YN/A

SUNSHINE BIOPHARMA INC / SBFM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SUNSHINE BIOPHARMA INC?

ChartMill assigns a fundamental rating of 4 / 10 to SBFM.


What is the valuation status of SUNSHINE BIOPHARMA INC (SBFM) stock?

ChartMill assigns a valuation rating of 1 / 10 to SUNSHINE BIOPHARMA INC (SBFM). This can be considered as Overvalued.


Can you provide the profitability details for SUNSHINE BIOPHARMA INC?

SUNSHINE BIOPHARMA INC (SBFM) has a profitability rating of 2 / 10.


What is the financial health of SUNSHINE BIOPHARMA INC (SBFM) stock?

The financial health rating of SUNSHINE BIOPHARMA INC (SBFM) is 6 / 10.